Soehnke Voss, a business development manager at Avanti and Croda, delivered this presentation on the advancements in lipid nanoparticles (LNPs) and their applications. He began by highlighting the versatility of lipids, which have garnered significant attention for their ability to deliver RNA, particularly after their use in the COVID-19 vaccines. However, he emphasised that these molecules are also effective in delivering many other active pharmaceutical ingredients (APIs) such as proteins, adjuvant systems, and small molecules.
Voss focused on LNPs, explaining their unique structure, which includes an electron-dense core composed of cationic lipids bound to negatively charged nucleic acids. This structure is surrounded by sterols and structural lipids that provide stability and shape. He discussed the role of different lipids in LNP formulation, such as DSPC, which is commonly used due to its stability and cylinder shape.
He also addressed the challenges in the field, including the stability of LNPs at higher temperatures, varying payloads, and the PEG dilemma. Some customers prefer PEG lipids for their stealth properties, while others avoid them due to the induction of anti-PEG antibodies. Voss introduced alternatives like poly-sarcosine lipids, which offer similar properties with improved transfection and safety profiles.
Voss then delved into targeting delivery, a hot topic in the field. He explained the two main strategies: active targeting, which involves binding targeting molecules to the particle's surface, and passive targeting, which changes the LNP's physical properties for organ trafficking. He provided examples of lipids used for targeting, such as PEG lipids with maleimides for binding to thiol groups and lipids suitable for click chemistry.
He concluded by discussing the extensive range of lipids available in Croda’s portfolio, including over 2000 research-quality lipids and more than 25 GMP-quality lipids. Voss emphasised their commitment to innovation and custom lipid production to meet specific research or GMP quality needs.
